Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Estramustine Phosphate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 5/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 4/20 | 1.00 |
| ▸ | PTPN11 | Q06124 | 2/20 | 1.00 |
| ▸ | INPPL1 | O15357 | 1/20 | 1.00 |
| ▸ | PTPN1 | P18031 | 1/20 | 1.00 |
| ▸ | DRD1 | P21728 | 1/20 | 1.00 |
| ▸ | PTPN6 | P29350 | 1/20 | 1.00 |
| ▸ | KDR | P35968 | 1/20 | 1.00 |
| ▸ | RECQL | P46063 | 2/20 | 0.76 |
| ▸ | BLM | P54132 | 1/20 | 0.76 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.66 |
| ▸ | MAPT | P10636 | 4/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.59 |
| ▸ | TP53 | P04637 | 3/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.59 |
| ▸ | MEN1 | O00255 | 4/20 | 0.59 |
| ▸ | THRB | P10828 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 4/20 | 0.54 |
| ▸ | ATM | Q13315 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Estramustine Phosphate SCHEMBL13545664 | 1.00 | ESR1 (1.00) | ESR1ADORA3PTPN11INPPL1PTPN1 | |
| Estramustine Phosphate SCHEMBL1649356 | 1.00 | ESR1 (1.00) | ESR1ADORA3PTPN11INPPL1PTPN1 | |
| Estramustine Phosphate SCHEMBL29379408 | 1.00 | ESR1 (1.00) | ESR1ADORA3PTPN11INPPL1PTPN1 | |
| Estramustine Phosphate SCHEMBL19436 | 0.93 | ESR1 (0.86) | ESR1ADORA3PTPN11INPPL1PTPN1 | |
| SCHEMBL18775356 | 0.89 | ESR1 (0.79) | ESR1ADORA3PTPN11INPPL1PTPN1 | |
| Estramustine SCHEMBL3625800 | 0.88 | RECQL (0.93) | ESR1ADORA3PTPN11INPPL1PTPN1 | |
| Estramustine SCHEMBL36761 | 0.88 | RECQL (0.93) | ESR1ADORA3PTPN11INPPL1PTPN1 | |
| Estramustine SCHEMBL8342744 | 0.88 | RECQL (0.93) | ESR1ADORA3PTPN11INPPL1PTPN1 | |
| Estramustine SCHEMBL22129748 | 0.88 | RECQL (0.93) | ESR1ADORA3PTPN11INPPL1PTPN1 | |
| SCHEMBL13545743 | 0.88 | ESR1 (0.78) | ESR1ADORA3PTPN11INPPL1PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3439640-B1 | NANOPARTICLES FOR DRUG DELIVERY TO TREAT BONE DISEASE | CLEVELAND CLINIC FOUND (US) | 2024-01-17 | — | — | EP | disclosed |
| EP-3471712-B1 | SMALL MOLECULE INHIBITORS OF ALDH AND USES THEREOF | UNIV MICHIGAN REGENTS (US) | 2024-01-03 | — | — | EP | disclosed |
| EP-3285583-B1 | SMALL MOLECULE INHIBITORS OF MCL-1 AND USES THEREOF | UNIV MICHIGAN REGENTS (US) | 2021-03-17 | — | — | EP | disclosed |
| US-20200338202-A1 | SHORT TAT OLIGOMERS FOR DRUG DELIVERY | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2020-10-29 | — | — | US | disclosed |
| EP-3125884-B1 | SMALL MOLECULE INHIBITORS OF MCL-1 AND USES THEREOF | UNIV MICHIGAN REGENTS (US) | 2019-11-06 | — | — | EP | disclosed |
| WO-2019005754-A1 | CANCER TREATMENT | THE CLEVELAND CLINIC FOUNDATION (US) | 2019-01-03 | — | — | WO | disclosed |
| EP-3131544-B1 | MDM2 INHIBITORS AND THERAPEUTIC METHODS USING THE SAME | UNIV MICHIGAN REGENTS (US) | 2018-12-12 | — | — | EP | disclosed |
| WO-2018081719-A1 | SMALL MOLECULE INHIBITORS OF NEK2 AND USES THEREOF | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2018-05-03 | — | — | WO | disclosed |
| EP-2911748-B1 | CANCER STEM CELL VACCINATION AND TREATMENT | UNIV MICHIGAN REGENTS (US) | 2018-03-14 | — | — | EP | disclosed |
| EP-2831067-B1 | SMALL MOLECULE INHIBITORS OF MCL-1 AND USES THEREOF | UNIV MICHIGAN REGENTS (US) | 2017-11-01 | — | — | EP | disclosed |
| EP-2141173-B1 | Methods and compositions for the inhibition of gene expression | PRONAI THERAPEUTICS INC (US) | 2013-01-02 | — | — | EP | disclosed |
| US-8163805-B2 | Small molecule antagonists of Bcl-2 family proteins | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2012-04-24 | — | — | US | disclosed |
| EP-1718767-B1 | COMPOSITIONS FOR TREATING BREAST AND PANCREATIC CANCER | UNIV MICHIGAN (US) | 2012-04-11 | — | — | EP | disclosed |
| US-20120003150-A1 | THERAPEUTIC RIBONUCLEASES | QUINTESSENCE BIOSCIENCES, INC. (US) | 2012-01-05 | — | — | US | disclosed |
| US-8088931-B2 | Small molecule inhibitors of MDM2 and the uses thereof | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2012-01-03 | — | — | US | disclosed |
| EP-2369014-A1 | Compositions and methods for characterizing, regulating, diagnosing and treating cancer | The Regents Of The University Of Michigan Office Of Technology Transfer (US) | 2011-09-28 | — | — | EP | disclosed |
| US-20110135710-A1 | Methods and Compositions for the Inhibition of Gene Expression | PRONAI THERAPEUTICS, INC. (US) | 2011-06-09 | — | — | US | disclosed |
| US-7932382-B2 | Amide substituted heterocylic compound; anticarcinogen; inducing apoptotic cell death, sensitizing cells to inducers of apoptosis | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2011-04-26 | — | — | US | disclosed |
| US-20110092452-A1 | COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING PANCREATIC CANCER | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2011-04-21 | — | — | US | disclosed |
| EP-2141173-A1 | Methods and compositions for the inhibition of gene expression | Pronai Therapeutics, Inc. (US) | 2010-01-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200338202-A1 | SHORT TAT OLIGOMERS FOR DRUG DELIVERY | ACIN1, MYCBP, STAT3 | ESR1 1401/4885ADORA3 3802/4885PTPN11 4230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.